August 17, 2017
Postmenopausal women who use vaginal estrogen are not at increased risk for cardiovascular events or cancer compared with those who do not use vaginal estrogen, suggesting the safety and efficacy of the therapy, according to findings published in Menopause.
Carolyn J. Crandall, MD, MS, of the department of medicine at the University of California, Los Angeles, and colleagues evaluated data from the Women’s Health Initiative observational study on 32,433 postmenopausal women without hysterectomy (3,003 users of vaginal estrogen during follow-up) and 14,133 postmenopausal women with hysterectomy (1,207 users of vaginal estrogen during follow-up). Researchers sought to determine the association between the use of estrogen and risk for a global index event, defined as time to first occurrence of coronary heart disease, invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer or death from any cause. Follow-up was a mean of 6.4 years. The mean age of participants who never used vaginal estrogen was 64.8 years, and mean age of participants who used vaginal estrogen during follow-up was 65.5 years.